Reteplase plus abciximab and reteplase alone led to similar 30-day mortality rates in acute MI
- PMID: 11874267
Reteplase plus abciximab and reteplase alone led to similar 30-day mortality rates in acute MI
Comment on
-
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial.Lancet. 2001 Jun 16;357(9272):1905-14. doi: 10.1016/s0140-6736(00)05059-5. Lancet. 2001. PMID: 11425410 Clinical Trial.